<DOC>
	<DOCNO>NCT02276833</DOCNO>
	<brief_summary>Autologous adipose-derived stromal vascular fraction ( SVF ) use treat 10 osteoarthritic knee grade II III ( K-L scale ) IRB-approved protocol feasibility safety study . The adipose-derived SVF obtain disaggregation lipoaspirate resuspension SVF 3 ml Lactated Ringer 's Solution , mean 48 million nucleated SVF cell mean viability 78 % , inject per knee . Cell suspension inject intra-articular space use ultrasound guidance . At 12 week post-op 10 knee show decreased pain increase mobility , statistically significant ( α = .01 ) . Nine ten knee report either maximum possible significant decrease pain . No infection , acute pain flare , adverse event report . Patient age range 52 - 69 year mean 59 year .</brief_summary>
	<brief_title>Use Autologous Adipose-Derived Stromal Vascular Fraction Treat Osteoarthritis Knee</brief_title>
	<detailed_description>Methods : Adipose Harvest . Using oral parenteral sedation , standard wet solution ( 1 liter Lactated Ringer 's , 50 milligram 1 % lidocaine , 1 cc 1:1000 epinephrine ) infuse small incision create tip # 11 scalpel blade abdomen flank use standard multi-hole infusion cannula . A super-wet plus technique ( 2 volume wet solution 1 volume propose fat aspirate ) use infuse solution deep superficial fat compartment . Twenty minute allow maximum vasoconstrictive effect epinephrine . Fat harvest use standard Suctioned-Assisted Liposuction ( SAL ) method 3mm cannula approximately .5 - .7 atmosphere vacuum , aspirate approximately 200-300 cc lipoaspirate sterile tissue processing container ( GID SVF-1 , Lousiville , CO ) knee treat . Adipose process method . Lipoaspirate harvest processed way generation SVF within single GID SVF-1 sterile disposable device . The GID SVF-1 unit contain wash mechanism , mesh filter , centrifuge capability device . After harvest lipoaspirate wash three time 37C Lactated Ringer 's Solution 20 mg Cipro 5,000 unit heparin per liter fluid portion remove use mesh filter system , leave dry adipose inside canister . The canister weigh determine amount dry adipose available processing . The washed adipose disaggregated use Type I collagenase ( Worthington , Lakewood , NJ ) concentration 200 CDU/ml total catalytic volume total catalytic volume volume adipose tissue plus equal volume 37C Lactated Ringer 's Solution . The collagenase inject canister sterile .22 micron filter ( Millex-MP , Millipore , Cork , Ireland ) . The device adipose , buffer , collagenase place incubated shaker 40 minute 38C 150 RPM , see Figure 1 . After disaggregation human albumin solution add achieve concentration 2.5 % stop collagenase activity . The device centrifuge 800 g 10 minute . The supernatant , include float cell debris aqueous phase , remove use port top device discard . The SVF pellet bottom resuspend 10 ml sterile LR access via central port device use 14G 5.5 inch spinal needle ( Abbocath-T , Hospira , Sligo , Ireland ) . A sample 0.5 ml resuspension collect 1.5 cc Eppendorf tube use cell count assay . The resuspended SVF cell concentrate 3 ml dose use sterile 15 ml Falcon tube 400 g 4 minute . SVF count method . The SVF cell count viability assess use ADAM MC image cytometry system ( Bulldog Bio , Portsmouth , NH ) . The ADAM MC use propidium iodide stain count viable non-viable nucleated cell . A 100 µL aliquot assay sample dilute 1:5 ratio ( 1 part sample 5 part sterile LR ) adjust sample within operate limit ADAM MC . The differential stain apply aliquot load disposable cassette utilized ADAM device . The result ADAM count device provide concentration SVF cell resuspension syringe percentage viability . The total volume resuspension syringe multiply concentration give total number resuspend mononucleated cell ( adipose cell , RBCs , fragment include count process ) . Injection image guidance method . The patient place supine position area lateral suprapatellar region knee prepare usual sterile fashion use iodine prep solution ( 1 % Iodophor ) follow 70 % Isopropyl Alcohol solution . This location use due ease access intra-articular space avoid inject fat pad knee . No sedation pain medication administer patient . An ethylchloride topical anesthetic spray lateral knee skin color change white . Lidocaine local anesthetic inject use 25 gauge needle numb skin subcutaneous tissue . Using M-Turbo Sonosite ultrasound system , joint space identify live ultrasound guidance knee aspirate use 18 gauge/1.5 inch needle , fluid available aspiration . Then 3 cc buffer solution SVF slowly inject intra-articular space 18 gauge/1.5 inch needle . The needle remove direct pressure injection site place approximately ten ( 10 ) second . Hemostasis injection confirm , injection site clean alcohol wipe cover sterile band-aid . The patient give crutch ask non-weight bearing inject knee two ( 2 ) day . The patient allow bend flex knee long non-weight bearing condition maintain . Pain mobility assessment method . Assessment knee pain do use PROMIS pain instrument , validate pain scale system develop fund NIH . PROMIS ( Patient Reported Outcomes Measurement Information System ) system measure patient report health status physical , mental , social well-being , include three measurement pain ( www.nihpromis.org ) . The PROMIS Pain Intensity instrument ( 3a ) ass much person hurt . The PROMIS Pain Behavior instrument ( Bank 1.0 ) measure behavior indicate others individual experience pain . The PROMIS Pain Interference instrument ( Bank 1.0 ) measure consequence pain relevant aspects one 's life . Patient response convert numeric value validate scale . Responses question pain instrument range 1 5 ( 1=not , 2=a little bit , 3=somewhat , 4=quite bit , 5=very much ) , sum number question bank create raw score . The raw score convert standardized score use iterative response method mean 50 SD 10 , base large sample general population United States . The validated PROMIS pain scale provide interval data allows calculation mean SD , use t-tests significance . Data record pre-operatively ( time 0 ) , follow-up point 2 week , 4 week , 6 week , 12 week . Additionally patient ask respond pain mobility questionnaire one question pain one question mobility . The questionnaire ask patient compare increase/decrease pain mobility relative surgery , use ± 1-5 scale , see Figure 2 . On scale negative number correspond decrease pain/mobility , positive number correspond increase pain/mobility . This questionnaire provide ordinal data allows calculation median significance use Wilcoxon Ranked Sums nonparametric testing .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Study Subject voluntarily give write Informed Consent participate study sign Health Insurance Portability Accountability Act ( HIPAA ) authorization study procedure perform . The age range 2070 year old . Both female male participant eligible . Females must nonpregnant childbearing age pregnancy test onsite SMASA RENEW day , prior , surgery ( Visit # 2 ) . Participants good health ( ASA Class III ) BMI &lt; 35 Failed regimen antiinflammatory systemic medicine and/or physical therapy . Knee pain grade great 4 10 . Mild moderate arthritis diagnose standard xray MRI study . Patients eligible inoffice surgical procedure SMASA RENEW . Participants allergic lidocaine , epinephrine , valium . Must speak , read understand English . Outside age range ( 2070 year old ) . BMI Index great 35 . Severe end stage osteoarthritis , Grade IV , diagnose plain xray MRI study . Hyaluronic acid gel injection affect knee joint within last six month . Corticosteroid injection affect knee joint within past 3 month . Current use oral/systemic steroid . History bleed disorder , anticoagulation therapy stop 14 day prior injection , uncontrolled diabetes mellitus , immunodeficiency disorder ( HIV ) , lipoatrophy disorder ( scleroderma , lupus etc . ) , rheumatoid arthritis medical condition cause chronic clinically significant pain . Allergic lidocaine , epinephrine , valium sodium phosphate . Individuals diminish decisionmaking capacity include research study . All smoker tobacco user . Current use antiinflammatory anticoagulation medication affect bleed bleeding disorder .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>